What is nanoMAG?
nanoMAG operates at the intersection of advanced materials science and nephrology, focusing on the development of bioabsorbable magnesium implants. The company's flagship innovation, the BioFlow Vascular Scaffold Device, is engineered to mitigate the high failure rates associated with traditional arteriovenous fistulas in hemodialysis patients. By utilizing a patented magnesium alloy that naturally resorbs into the body, nanoMAG aims to reduce the incidence of stenosis and thrombosis, thereby improving patient outcomes and reducing the frequency of secondary surgical interventions. As the global burden of chronic kidney disease continues to rise, the company's focus on durable, biocompatible vascular solutions positions it as a critical player in the medical device sector.
How much funding has nanoMAG raised?
nanoMAG has raised a total of $77K across 1 funding round:
Debt
$77K
Debt (2021): $77K with participation from PPP
Key Investors in nanoMAG
PPP
Public-Private Partnership
What's next for nanoMAG?
With this significant Series B/C stage financing, nanoMAG is expected to prioritize the expansion of its clinical trial infrastructure and the refinement of its manufacturing processes to meet stringent quality standards. The strategic roadmap likely includes pursuing regulatory milestones necessary for commercialization in key markets, including the United States. As the company transitions from a research-heavy entity to a clinical-stage commercial enterprise, the focus will shift toward establishing robust clinical evidence to support the long-term efficacy of its BioMg platform. Future growth will be contingent upon successful regulatory navigation and the ability to scale production while maintaining the high-precision requirements of its proprietary alloy technology.
See full nanoMAG company page
